Obesity and atherogenic dyslipidemia.

Area of Science:

• Cardiovascular Science
• Metabolic Research
• Molecular Biology

Background:

• Obesity is a major risk factor for coronary heart disease (CHD).
• Atherogenic dyslipidemia, characterized by elevated triglycerides and low high-density lipoprotein (HDL) cholesterol, is a key mediator linking obesity to CHD.
• Understanding the molecular mechanisms is crucial for developing targeted interventions.

Purpose of the Study:

• To review the epidemiology of atherogenic dyslipidemia.
• To detail the molecular mechanisms of adipocyte function in obesity and its impact on lipoprotein metabolism.
• To discuss the pathophysiology of low HDL cholesterol in obesity and its cardiovascular implications.

Main Methods:

• Literature review focusing on molecular mechanisms.
• Analysis of adipocyte function in healthy versus obese states.
• Examination of apoB-containing lipoprotein assembly and metabolism.

Main Results:

• Obesity significantly alters adipocyte function, influencing lipoprotein metabolism.
• Specific molecular pathways connect obesity to the development of atherogenic dyslipidemia.
• Low HDL cholesterol in obesity is linked to altered lipoprotein metabolism and increased cardiovascular risk.

Conclusions:

• Obesity-induced changes in adipocyte function are central to atherogenic dyslipidemia.
• Targeting molecular mechanisms of adipocyte function and lipoprotein metabolism may reduce cardiovascular risk in obesity.
• Further research into HDL cholesterol pathophysiology in obesity is warranted for effective CHD prevention.